StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

Stock analysts at StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report issued on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

CPIX stock opened at $2.33 on Monday. The stock has a market capitalization of $32.72 million, a PE ratio of -3.03 and a beta of 0.13. Cumberland Pharmaceuticals has a 12-month low of $1.04 and a 12-month high of $3.05. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The stock’s 50 day simple moving average is $1.73 and its 200 day simple moving average is $1.49.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.